tacrolimus topical (Protopic)
Jump to navigation
Jump to search
Indications
- topical treatment of atopic dermatitis
- reserve for patients who cannot use or do not respond to topical steroids
Dosage
0.1% & 0.03%
Pharmacokinetics
- minimal systemic absorption, especially with intact skin
Adverse effects
- photosensitivity
- increased risk of skin cancer[2]
Mechanism of action
- suppresses T-cells that cause skin inflammation
More general terms
References
- ↑ Prescriber's Letter 8(2):9 2001
- ↑ 2.0 2.1 Prescriber's Letter 12(4): 2005 FDA Public Health Advisory Elidel (pimecrolimus) Cream and Protopic (tacrolimus) Ointment Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210407&pb=PRL (subscription needed) http://www.prescribersletter.com http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01343/htm
- ↑ Journal Watch 25(9):75, 2005 Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005 Mar 5;330(7490):516. Epub 2005 Feb 24. Review. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/15731121 <Internet> http://bmj.bmjjournals.com/cgi/content/full/330/7490/503